Description
Clindamycin is a lincosamide antibiotic that exhibits antibacterial, anti-protozoan, anti-parasitic, and antimalarial activities. Clindamycin displays efficacy against anaerobic gram negative bacteria, Streptococcus, and Staphylococcus (particularly MRSA). Clindamycin binds 23S rRNA of the ribosomal 50S subunit, preventing translocation and protein synthesis. When co-administered with other anti-parasitic compounds, clindamycin is also occasionally used to treat Plasmodium infection.
References
Takem EN, D'Alessandro U. Malaria in pregnancy. Mediterr J Hematol Infect Dis. 2013;5(1):e2013010. PMID: 23350023.
Sireesha P, Setty CR. Detection of various types of resistance patterns and their correlation with minimal inhibitory concentrations against clindamycin among methicillin-resistant Staphylococcus aureus isolates. Indian J Med Microbiol. 2012 Apr-Jun;30(2):165-9. PMID: 22664431.
Wilson DN. On the specificity of antibiotics targeting the large ribosomal subunit. Ann N Y Acad Sci. 2011 Dec;1241:1-16. PMID: 22191523.
Schlünzen F, Zarivach R, Harms J, et al. Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21. PMID: 11677599.
